Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

232.16

-0.61 (0.26%)

as of Jun 8, 2026, 8:00:00 pm Market Open.

698 watching

Investor Insights

Jun 8, 2026, 12:00 am

This summary was created by AI, based on 12 opinions in the last 12 months.

Johnson & Johnson (JNJ) has been experiencing a transformative period, especially following the spinoff of its orthopedics division, allowing it to focus more on pharmaceuticals and medical devices. Experts have highlighted the company's strong drug pipeline and robust performance in its core pharmaceutical business, which has led to a significant increase in stock value this year. Despite some concerns regarding ongoing talcum powder litigation and its past underwhelming performance, many analysts believe the legal risks are diminishing. The stock is seen as a better long-term hold, with potential dividend growth, especially amidst a broader economic context affecting consumer products. Overall, JNJ is viewed as an attractive investment, particularly when bought on weakness, with the valuation appearing favorable due to its premium position in the healthcare sector.

Consensus

Buy

Valuation

Fair Value

Similar

TOP PICK

Feels you can get a double-digit return out of this one. Good opportunities for earnings improvement. Good price.

BUY

He likes it for the health care products, more than for the pharmaceutical and medical devices. The stent business is under serious question right now. Trades at a very reasonable PE.

DON'T BUY

Looking a lot better than it did, but still overvalued. His model price is $56.90. Negative 8% differential.

BUY

Likes this a lot. A multinational which pays a dividend.

BUY

A great company and well run. While diversified with pharmaceuticals and consumer products. Throws off lots of free cash flow.

HOLD

This is a company that will have lower return, but more stable. There is a good opportunity for a return in the future.

DON'T BUY

Model price of $57.07, a negative 14% differential. Typical of consumer staples where the market rotated into heavily this year.

BUY

Household products form a base for this company, and he sees the pharmaceuticals as an add-on. Excellent earnings.

BUY

Looks interesting. More consumer products than some of the other large pharmas.

DON'T BUY

His model price is $53.22 which is a negative 17% differential. If you want a great company in your portfolio for 20/30 years, this may be the one, or if you're trying to beat the S&P 500.

BUY

All the major drug stocks are starting to act better. In this type of market, money moves from risky stocks to defensive stocks. A good place to be.

DON'T BUY

The “gold standard” in the healthcare industry. The problem is when you look at earnings growth in healthcare it is the lowest and has the lowest expectations. Would avoid this sector.

BUY

A hybrid. Part pharmaceutical/medical devices and part consumer products. Just in the process of buying Pfizer's (PFE-N) consumers product division. Has had fabulous management. Great growth in earnings.

TOP PICK

2.5% dividend. Gives you US exposure if you need that. Very defensive in terms of the drug companies. Not highly leveraged. Very good product mix. A defensive holding.

BUY

Stock gives you a split between consumer products, medical devices and pharmaceuticals. Pharmaceuticals are weak because of patents coming off. Medical device sector will face higher competition. Want to use cash from the consumer products for R&D. Dividends have gone up recently. Won't give you great growth, but a good conservative holding. Only buy 1/2 a position now and add more later.

Showing 541 to 555 of 626 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)